Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors.
James M ClearyVictoria WangRebecca S HeistE Scott KopetzEdith P MitchellJames A ZwiebelKevin S KapnerHelen X ChenShuli LiRobert C GrayLisa Meier McShaneLawrence V RubinsteinDavid R PattonFunda Meric-BernstamMelissa S DillmonP Mickey WilliamsStanley R HamiltonBarbara A ConleyAndrew J AguirrePeter J O'DwyerLyndsay N HarrisCarlos L ArteagaHelen X ChenKeith T FlahertyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Single-agent binimetinib did not show promising efficacy in NRAS-mutated cancers. The observation of increased OS and PFS in patients with codon 61 NRAS-mutated colorectal cancer merits further investigation.